Does Rallies show 13F holders for NSPR?

Yes. Rallies tracks hedge fund and 13F ownership data for NSPR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NSPR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NSPR. It does not provide personalized investment advice.

NSPR (InspireMD, Inc.) Stock Analysis - Hedge Fund Holdings

InspireMD, Inc. (NSPR) is a publicly traded Healthcare sector company. As of May 21, 2026, NSPR trades at $1.00 with a market cap of $49.18M and a P/E ratio of -1.33. NSPR moved +1.00% today. Year to date, NSPR is -48.19%; over the trailing twelve months it is -54.34%. Its 52-week range spans $0.97 to $3.80. Analyst consensus is strong buy with an average price target of $3.67. Rallies surfaces NSPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NSPR stock?

Hedge funds tracked by Rallies that own NSPR include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for InspireMD, Inc..

NSPR Key Metrics

Key financial metrics for NSPR
Metric	Value
Price	$1.00
Market Cap	$49.18M
P/E Ratio	-1.33
EPS	$-0.76
Dividend Yield	0.00%
52-Week High	$3.80
52-Week Low	$0.97
Volume	0
Avg Volume	0
Revenue (TTM)	$8.98M
Net Income	$-48.79M
Gross Margin	29.50%

Top Hedge Funds Holding NSPR

Orbimed Advisors holds 3.13M shares of NSPR, changed +0.00% as of Mar 31, 2026.

Latest NSPR News

InspireMD Q1 Revenue Soars 122% to $3.4M, EPS Beats Estimates — May 5, 2026
InspireMD Q1 Revenue Soars 122% to $3.4M, Secures FDA IDE Approval — May 4, 2026
InspireMD Q4 Revenue Soars 62%, Net Loss Widens to $11.8M — Mar 18, 2026

Recent NSPR Insider Trades

Slosman Marvin bought 21.00K (~$25.20K) on May 12, 2026.
Stuka Paul bought 10.00K (~$11.90K) on May 11, 2026.
Stuka Paul bought 10.00K (~$11.90K) on May 11, 2026.

NSPR Analyst Consensus

3 analysts cover NSPR: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $3.67.

Common questions about NSPR

Who owns NSPR stock?: Hedge funds tracked by Rallies that own NSPR include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for InspireMD, Inc..
Does Rallies show 13F holders for NSPR?: Yes. Rallies tracks hedge fund and 13F ownership data for NSPR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NSPR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NSPR. It does not provide personalized investment advice.